Asset
Sapropterin Dihydrochloride
BioMarin Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00789568 | phase1 | completed | 2008-10-01 | 2009-01-01 | BioMarin Pharmaceutical | A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects |
| NCT00445978 | phase2 | completed | 2007-05-01 | 2008-08-01 | BioMarin Pharmaceutical | A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease |
| NCT00403494 | phase2 | completed | 2006-12-01 | 2008-11-01 | BioMarin Pharmaceutical | A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease |
| NCT00532844 | phase2 | completed | 2007-09-01 | 2008-11-01 | BioMarin Pharmaceutical | A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction |
| NCT00225615 | phase3 | completed | 2005-11-01 | — | BioMarin Pharmaceutical | A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 022181 | NDA | BIOMARIN PHARMACEUTICAL INC |
| NDA 205065 | NDA | BIOMARIN PHARMACEUTICAL INC |
Marketed products (3)
- KUVAN
- KUVAN
- KUVAN